Ratio Review: Analyzing Recursion Pharmaceuticals Inc (RXRX)’s Price-to-Cash and Price-to-Free Cash Flow

Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.

After finishing at $8.79 in the prior trading day, Recursion Pharmaceuticals Inc (NASDAQ: RXRX) closed at $8.59, down -2.28%. In other words, the price has decreased by -$2.28 from its previous closing price. On the day, 2.56 million shares were traded. RXRX stock price reached its highest trading level at $8.765 during the session, while it also had its lowest trading level at $8.43.


Our goal is to gain a better understanding of RXRX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.70 and its Current Ratio is at 4.70. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on May 22, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $8.

On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.

On September 16, 2022, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $20.KeyBanc Capital Markets initiated its Overweight rating on September 16, 2022, with a $20 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 02 ’24 when Gibson Christopher sold 50,000 shares for $8.47 per share. The transaction valued at 423,500 led to the insider holds 834,820 shares of the business.

Gibson Christopher sold 50,000 shares of RXRX for $386,500 on May 01 ’24. The Chief Executive Officer now owns 863,524 shares after completing the transaction at $7.73 per share. On Apr 30 ’24, another insider, Borgeson Blake, who serves as the Director of the company, sold 11,447 shares for $7.95 each. As a result, the insider received 90,964 and left with 7,218,414 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2040313984 and an Enterprise Value of 1721709312. For the stock, the TTM Price-to-Sale (P/S) ratio is 45.77 while its Price-to-Book (P/B) ratio in mrq is 4.33. Its current Enterprise Value per Revenue stands at 38.625 whereas that against EBITDA is -5.287.

Stock Price History:

The Beta on a monthly basis for RXRX is 0.87, which has changed by 0.59528136 over the last 52 weeks, in comparison to a change of 0.2537824 over the same period for the S&P500. Over the past 52 weeks, RXRX has reached a high of $16.75, while it has fallen to a 52-week low of $4.92. The 50-Day Moving Average of the stock is -11.81%, while the 200-Day Moving Average is calculated to be -6.15%.

Shares Statistics:

The stock has traded on average 6.43M shares per day over the past 3-months and 4412350 shares per day over the last 10 days, according to various share statistics. A total of 226.26M shares are outstanding, with a floating share count of 162.04M. Insiders hold about 31.78% of the company’s shares, while institutions hold 72.05% stake in the company. Shares short for RXRX as of 1713139200 were 38704268 with a Short Ratio of 6.02, compared to 1710460800 on 43520191. Therefore, it implies a Short% of Shares Outstanding of 38704268 and a Short% of Float of 24.58.

Earnings Estimates

At present, 6.0 analysts are actively evaluating the performance of Recursion Pharmaceuticals Inc (RXRX) in the stock market.On average, analysts expect EPS of -$0.42 for the current quarter, with a high estimate of -$0.39 and a low estimate of -$0.46, while EPS last year was -$0.34. The consensus estimate for the next quarter is -$0.42, with high estimates of -$0.38 and low estimates of -$0.46.

Analysts are recommending an EPS of between -$1.49 and -$2.1 for the fiscal current year, implying an average EPS of -$1.72. EPS for the following year is -$1.86, with 8.0 analysts recommending between -$1.12 and -$3.5.

Revenue Estimates

6 analysts predict $12.65M in revenue for the current quarter. It ranges from a high estimate of $20.8M to a low estimate of $10M. As of the current estimate, Recursion Pharmaceuticals Inc’s year-ago sales were $12.13MFor the next quarter, 6 analysts are estimating revenue of $13.17M. There is a high estimate of $20.8M for the next quarter, whereas the lowest estimate is $10.9M.

A total of 7 analysts have provided revenue estimates for RXRX’s current fiscal year. The highest revenue estimate was $83.3M, while the lowest revenue estimate was $43M, resulting in an average revenue estimate of $56.16M. In the same quarter a year ago, actual revenue was $44.58MBased on 7 analysts’ estimates, the company’s revenue will be $88.43M in the next fiscal year. The high estimate is $254.9M and the low estimate is $41.89M.

Most Popular

[the_ad id="945"]